Clinical Trial VICCHEM1346


A Phase II, Randomized, Comparative Trial of Standard of Care, with or without Midostaurin to Prevent Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia

Principal Investigator(s)

Sanjay Mohan


  • Protocol No. VICCHEM1346
  • Open Date: 01/21/2014
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To determine if the addition of midostaurin to standard of care (SOC) therapy reduces relapse after at least 18 months of follow-up following allogeneic HSCT in FLT3-ITD mutant AML patients in first complete remission (CR1)
  • Disease Sites: Leukemia; Hematologic
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Midostaurin (PKC412)
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01883362
  • Secondary Protocol No: CPKC412AUS23



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.